Gelesis Holdings, Inc. Overview
Pro stress-test →Gelesis Holdings, Inc. was a Boston-based biotherapeutics company specializing in superabsorbent hydrogel therapies for weight management and gastrointestinal-related chronic diseases. The company's flagship product, Plenity (Gelesis100), received FDA clearance (April 2019) as a non-systemic, non-stimulant aid for weight management. However, Gelesis filed for Chapter 7 liquidation in October 2023.
Strategic Profile
Pro stress-test →Gelesis pioneered a biomimetic approach using naturally-derived hydrogels that mechanically expanded in the stomach to create satiety without systemic effects. The company pursued a diverse pipeline including Gelesis200 for Type 2 Diabetes and investigational candidates for NASH and functional constipation. Despite FDA approval and clinical validation, commercialization challenges and market headwinds led to financial distress.
Competitive Landscape
Pro stress-test →Gelesis competed in the obesity treatment space against pharmaceutical and medical device competitors including Vivus (oral GLP-1 agonists), NGM Biopharmaceuticals (metabolic disease focus), and oral weight-loss medications from major pharma. The rise of GLP-1 receptor agonists (semaglutide, tirzepatide) by Novo Nordisk and Eli Lilly created significant headwinds for mechanical/non-systemic approaches. Gelesis's mechanical-only mechanism and limited reimbursement differentiated but ultimately constrained its market opportunity.
Industry Context
Gelesis Holdings, Inc. operates in Weight management medical devices and therapies.
Key facts
Founded: 2006 · Headquarters: Boston, MA, USA · Employees: 93 (as of 2023) · Revenue: $12.1M (trailing twelve months as of June 2023) · Market cap: $3.62M (as of August 2023)